Following adults hospitalized with lung airway diseases and other illnesses
Follows adults hospitalized for COPD, asthma or bronchiectasis flares, tracking other illnesses.
Plain-language title generated from the registry record
Registry title: Chronic Airway Disease and Multimorbidity Cohort
Key facts
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Wuhan, Xi'an, and Zhengzhou, ChinaSee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital because of a flare-up of COPD, asthma or bronchiectasis.
- Age
- COPD: 40 years or older. Asthma and bronchiectasis: 18 years or older.
- Sex
- Men and women can join.
- Disease stage
- Hospital admission for an acute flare-up of COPD, uncontrolled asthma, or a flare-up of bronchiectasis.
Main reasons for not taking part
- Cannot do spirometry (a breathing test) once stable
- Expected to live less than 1 month
- Refuses to sign the informed consent form
- Chest imaging showing new patchy shadows, solid shadows, ground glass shadows or interstitial changes
- Cystic fibrosis, interstitial lung disease or other lung diseases with tractional bronchial dilatation
Read by machine on 12 November 2026.
Where in China
- National Center for Respiratory Medicine, China-Japan Friendship HospitalBeijing, ChinaContact: Ke Huang, MDTaking people
- The Second Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Huihui Zeng, MDTaking people
- West China Hospital of Sichuan UniversityChengdu, ChinaContact: Diandian Li, MDTaking people
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaContact: Xin Chen, MDTaking people
- Ruijin Hospital Affiliated to Shanghai Jiao Tong UniversityShanghai, ChinaContact: Wei Chen, MDTaking people
- The First Affiliated Hospital of China Medical UniversityShenyang, ChinaContact: Chenye Feng, MDTaking people
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, ChinaContact: Qiong Zhou, MDTaking people
- The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaContact: Ming Zhang, MDTaking people
- Henan Provincial People's HospitalZhengzhou, ChinaContact: Quncheng Zhang, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT06798077
- Record updated
- 17 February 2025
- Original description
Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated.Read full original descriptionShow less
Chronic Airway Disease and Multimorbidity (CAM) Cohort: Protocol of a Prospective Multicenter Observational Cohort Study
Background: Chronic airway diseases (CAD), including chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis, are highly prevalent and cause serious disease burden. Multimorbidity is recognized to influence treatment decision and prognosis of patients with stable CAD. The impact of multimorbidity on exacerbation CAD is under investigated.
Methods: The Chronic Airway Disease and Multimorbidity (CAM) cohort study is a prospective, multicenter, observational study aiming to recruit a minimum of 2000 patients hospitalized for exacerbation of COPD, asthma or bronchiectasis. Comprehensive data, including demographics, medical history, comorbidities, lung function, echocardiography, microbiological profiles, radiology, quality of life and treatment will be collected at baseline during the hospitalization. Follow-up data indicating the impact of both CAD and multimorbidity will be collected at 1-, 3-, 6-, 9- and 12-months after hospital discharge. Biospecimens, including blood and bronchoalveolar lavage fluid, will be collected and analyzed for biomarker detecting. Primary outcome are length of hospital stay and re-exacerbation during fellow-up. Secondary outcomes include comorbidity pattern and its impact on respiratory symptoms burden, quality of life, pulmonary function and chest imaging as well as cost and healthcare utilization.
Conclusions: The knowledge generated from CAM cohort study will fill crucial gaps in understanding how multimorbidity affects CAD and facilitate evidence-based clinical practice in the future.
Inclusion: Patients with chronic obstructive pulmonary disease ≥40 years of age; patients with asthma and bronchiectasis ≥18 years of age; The primary diagnosis on admission was "acute exacerbation of chronic obstructive pulmonary disease, uncontrolled asthma, or acute exacerbation of bronchiectasis".
Exclusion: Patients with cystic fibrosis or with interstitial lung disease or other lung diseases with tractional branchial dilatation; Patients were unable to undergo spirometry during the stabilization period; Expected survival is less than 1 month; Refusal to sign an informed consent form; Chest imaging showed emerging patchy infiltrating shadows, lobar or segmental solid shadows, ground glass shadows, or interstitial changes with or without pleural effusion.